EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

Pernille D Haahr iD, Anette D Kjeldsen, Annette D Fialla, Anne-Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans-Jurgen Mager, Jean-Christophe Saurin, Jens Kjeldsen, Josefien Hessels und 7 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70273 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Pernille D Haahr und 18 weiteren Autor:innen. Beteiligte Einrichtung: VASCERN HHT Reference Centre and ENT Department, Odense University Hospital, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).

Aim

To report the experience of treatment with bevacizumab within European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN) centres.

Method

A retrospective analysis of the usage, availability, efficacy and safety in HHT patients treated with bevacizumab in European VASCERN centres.

Results

A total of 151 patients received treatment with bevacizumab in European VASCERN centres. Most patients were treated in Denmark, France and the Netherlands. There was an improvement in haemoglobin with a mean increase of 2.9 g/dL (95% confidence interval 2.4, 3.6) and significant reduction in the number of red blood cell transfusions. Cardiac output was measured and improved in 85% of patients treated for high output cardiac failure in relation to severe HAVM. No severe adverse events were recorded, but 70 patients experienced at least one adverse event.

Conclusion

Although this is a retrospective study, we demonstrated convincing efficacy of bevacizumab in the treatment of patients with HHT, with a good risk‐benefit balance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Telangiectasia, Hereditary HemorrhagicAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedHumansBevacizumabRetrospective StudiesMaleFemaleMiddle AgedAdultAgedEuropeTreatment OutcomeYoung AdultOff-Label UseAged, 80 and over

Stichwörter der Autor:innen

VASCERNbevacizumabhereditary haemorrhagic telangiectasia

Substanzen

BevacizumabAngiogenesis InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • VASCERN HHT Reference Centre and ENT Department, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • VASCERN HHT Reference Centre and Gastroenterology and Hepatology Department, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • VASCERN HHT Reference Centre and Genetic Department, Hospices Civils de Lyon, Lyon, France.
  • VASCERN HHT Reference Centre and Gastroenterology Department, ASST Maggiore Hospital, Crema, Italy.
  • VASCERN HHT Reference Centre and ENT Department, Essen University Hospital, Essen, Germany.
  • VASCERN HHT Reference Centre and Respiratory Department, St Antonius Hospital, Nieuwegein, The Netherlands.

ORCID-Profile: Pernille D Haahr

Zitieren

APA

Haahr, P. D., Kjeldsen, A. D., Fialla, A. D., Fargeton, A. E., Guilhem, A., Buscarini, E., Droege, F., Manfredi, G., Mager, H. J., Saurin, J. C., Kjeldsen, J., Hessels, J., Post, M. C., Mandic, R., Boerman, S., Kasper-Virchow, S., Möller, S., Geisthoff, U., & Dupuis-Girod, S. (2026). Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70273

Vancouver

Haahr PD, Kjeldsen AD, Fialla AD, Fargeton AE, Guilhem A, Buscarini E, et al. Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70273

BibTeX
@article{Haahr2026,
  author = {Haahr, Pernille D and Kjeldsen, Anette D and Fialla, Annette D and Fargeton, Anne-Emmanuelle and Guilhem, Alexandre and Buscarini, Elisabetta and Droege, Freya and Manfredi, Guido and Mager, Hans-Jurgen and Saurin, Jean-Christophe and Kjeldsen, Jens and Hessels, Josefien and Post, Marco C and Mandic, Robert and Boerman, Sanne and Kasper-Virchow, Stefan and Möller, Sören and Geisthoff, Urban and Dupuis-Girod, Sophie},
  title = {Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70273}
}
Kostenlos starten →